October 31st Options Now Available For TG Therapeutics (TGTX)

The article outlines two specific options strategies for TG Therapeutics (TGTX), currently trading at $31.86, offering defined risk/reward profiles. Investors interested in a lower entry point can sell a $31.00 strike put for a $1.75 premium, resulting in an effective cost basis of $29.25 if assigned, or a 5.65% return (41.21% annualized) if the option expires worthless (61% probability). Alternatively, a covered call strategy involves buying shares and selling a $33.00 strike call for $1.95, potentially yielding a 9.70% total return if the stock is called away, or a 6.12% premium (44.68% annualized) if the call expires worthless (50% probability), leveraging TGTX's implied volatility around 61-62%.

Analysis

The provided text outlines two specific, yield-focused options strategies for TG Therapeutics (TGTX), which is currently trading at $31.86. The analysis is purely technical, leveraging the stock's volatility profile to define risk and reward. For investors interested in acquiring the stock at a discount, selling the $31.00 strike put offers a $1.75 premium, lowering the effective cost basis to $29.25. Analytical models suggest a 61% probability of this out-of-the-money put expiring worthless, which would result in a 5.65% return on the cash commitment (41.21% annualized). For existing shareholders, a covered call strategy at the $33.00 strike provides a $1.95 premium, capping the total return at 9.70% if the stock is called away, but offering a 6.12% yield boost (44.68% annualized) if it expires worthless, an event with a 50% probability. The implied volatility for these options, at 61-62%, is slightly elevated compared to the trailing twelve-month historical volatility of 59%, indicating that option sellers are receiving a modest premium relative to recent price action. This analysis does not consider the company's fundamentals, which are noted as a critical, separate area for due diligence.

Key Decisions for Investors

• Investors bullish on TGTX but seeking a lower entry point than the current price of $31.86 could consider selling the $31.00 strike put to either acquire shares at an effective cost of $29.25 or generate a significant annualized yield if the stock remains above the strike.
• Current TGTX shareholders could evaluate the covered call strategy by selling the $33.00 strike call to generate immediate income and achieve a potential 9.70% total return, while acknowledging this action caps any further upside beyond $33.00 per share.
• Given that implied volatility (61-62%) is marginally higher than historical volatility (59%), conditions are slightly favorable for option-selling strategies, but these trades should be predicated on an investor's independent view of the stock's fundamental value and direction.
• These strategies are purely technical, so any position should be complemented by a thorough analysis of TG Therapeutics' business fundamentals, clinical pipeline, and broader biotech sector risks, which are not addressed in the article.